HOME Top Market Reports Liquid Biopsy Market by Cancer Type (Lung, Breast, Colorectal, Prostate, Liver), Circulating Biomarkers (Circulating Tumor Cells, Circulating Tumor DNA), Product (Instruments, Software), End User (Reference Laboratory, Research Centers) - Forecast to 2021

Liquid Biopsy Market by Cancer Type (Lung, Breast, Colorectal, Prostate, Liver), Circulating Biomarkers (Circulating Tumor Cells, Circulating Tumor DNA), Product (Instruments, Software), End User (Reference Laboratory, Research Centers) - Forecast to 2021

By: marketsandmarkets.com
Publishing Date: July 2016
Report Code: MD 4456

 

  Speak to Analyst Enquiry Before Buying  
purchase report
download pdf  request for customisation


The liquid biopsy market is expected to reach USD 1.66 Billion by 2021 from USD 0.58 Billion in 2016, growing at a CAGR of 23.4% during the forecast period of 2016 to 2021. Factors such as the growing incidence of cancer, benefits of liquid biopsy over solid tumor biopsy, technological advancements, availability of funding, and growing awareness about liquid biopsy through conferences and government initiatives are driving the growth of the market. However, the unclear regulatory and reimbursement scenario is a major area of concern in the market.

In this report, the liquid biopsy market is segmented on the basis of cancer type, circulating biomarkers, end users, products & services, and regions. Based on cancer type, the market is segmented into lung cancer, colorectal cancer, breast cancer, prostate cancer, liver cancer, and other cancers. The other cancers segment includes melanoma, bladder cancer, and ovarian cancer. In 2016, the lung cancer segment is expected to account for the largest share of the market, followed by breast cancer.

On the basis of circulating biomarkers, the liquid biopsy market is segmented into circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), Extracellular Vesicles (EVs), and other biomarkers (circulating RNA and proteins). In 2016, the circulating tumor cells segment is expected to account for the largest share of the global market, followed by the circulating tumor DNA segment. Similarly, based on products & services, the market is segmented into instruments, reagents, and services and software.

Based on end users, the liquid biopsy market is segmented into reference laboratories, hospital/physician laboratories, academic and research centers, and other end users. The other end-users segment includes pathology laboratories, public health laboratories, and small molecular laboratories.

In 2016, North America is expected to command the largest share of the liquid biopsy market. Factors such as easy accessibility and high adoption of advanced diagnostic technologies, such as PCR and NGS, among healthcare professionals; increasing prevalence of cancer in the U.S. and Canada; and continuous technological advancements in liquid biopsy are responsible for the large share of North America in the market. However, the Asia-Pacific liquid biopsy market is estimated to grow at the highest CAGR during the forecast period, primarily due to the increasing focus of players on this region.

The key players operating in liquid biopsy market are Biocept Inc. (U.S.), Myriad Genetics (U.S.), QIAGEN (Netherlands), Roche (Switzerland), Bio-Rad Laboratories Inc. (U.S.), Trovagene Inc. (U.S.), Guardant Health, Inc. (U.S.), Janssen Diagnostics, LLC (U.S.), Fraunhofer-Gesellschaft (Germany), and MDxHealth SA (U.S.).

Target Audience:

  • Pharmaceutical Companies
  • Biotechnology Companies
  • Research Institutes
  • Contract Research Organizations
  • Research and Consulting Companies
  • Liquid Biopsy Product Manufacturers and Distributors
  • Hospitals and Diagnostics Centers
  • Reference Laboratories
  • Government and Public Laboratories

To know about the assumptions considered for the study, download the pdf brochure

Scope of the Report:

This research report categorizes the liquid biopsy market into the following segments and subsegments:

  • Liquid Biopsy Market, by Type of Cancer
    • Lung Cancer
    • Breast Cancer
    • Colorectal Cancer
    • Prostate Cancer
    • Liver Cancer
    • Other Cancers (Melanoma, Bladder Cancer, and Ovarian Cancer)
  • Liquid Biopsy Market, by Products and Services
    • Instruments
    • Reagents
    • Services and Software
  • Liquid Biopsy Market, by Circulating Biomarkers
    • Circulating Tumor Cells (CTCs)
    • Circulating Tumor DNA (ctDNA)
    • Extracellular Vesicles (EVs)
    • Other Biomarkers (Circulating RNA and Protein)
  • Liquid Biopsy Market, by End User
    • Academic & Research Centers
    • Hospital and Physician Laboratories
    • Reference Laboratories
    • Others End User (Public Health Laboratories, Pathology Laboratories, and Small Molecular Laboratories)
  • Liquid Biopsy Market, by Region
    • North America
      • U.S.
      • Canada
    • Europe
    • Asia-Pacific
    • Rest of the World (RoW)

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

  • Company Information
    • Detailed analysis and profiling of additional market players (Up to 5)
    • Detailed analysis of liquid biopsy market in European and Asia-Pacific countries

Table of Contents

1 Introduction (Page No. - 15)
    1.1 Objectives of the Study
    1.2 Liquid Biopsy Market Definition
    1.3 Markets Scope
           1.3.1 Markets Covered
           1.3.2 Years Considered for the Study
    1.4 Currency
    1.5 Limitations
    1.6 Stakeholders

2 Research Methodology (Page No. - 18)
    2.1 Liquid Biopsy Market Size Estimation
    2.2 Liquid Biopsy Market Breakdown and Data Triangulation
           2.2.1 Key Data From Secondary Sources
           2.2.2 Key Data From Primary Sources
           2.2.3 Assumptions for the Study

3 Executive Summary (Page No. - 26)
    3.1 Introduction
    3.2 Current Scenario
    3.3 Future Outlook
    3.4 Conclusion

4 Premium Insights (Page No. - 31)
    4.1 Liquid Biopsy: Market Overview
    4.2 Geographic Analysis: Liquid Biopsy Market, By Circulating Biomarker
    4.3 Liquid Biopsy Market Size, By End User, 2016 vs 2021
    4.4 Liquid Biopsy Market Size, By Product, 2016 vs 2021
    4.5 Liquid Biopsy Market Size, By Circulating Biomarker, 2016 vs 2021
    4.6 Geographical Snapshot of the Liquid Biopsy Market

5 Market Overview (Page No. - 36)
    5.1 Introduction
    5.2 Market Dynamics
           5.2.1 Market Drivers
                    5.2.1.1 Increasing Number of New Cancer Cases
                    5.2.1.2 Benefits of Liquid Biopsy Over Surgical Biopsy
                    5.2.1.3 Technological Advancements to Boost Market Growth
                    5.2.1.4 Availability of Funding for Liquid Biopsy Research
                    5.2.1.5 Initiatives to Increase Awareness on Liquid Biopsy
           5.2.2 Market Restraints
                    5.2.2.1 Low Sensitivity and Specificity
           5.2.3 Market Opportunities
                    5.2.3.1 Focus on Inorganic Strategies
           5.2.4 Market Challenges
                    5.2.4.1 Unclear Regulatory and Reimbursement Scenario

6 Industry Insights (Page No. - 45)
    6.1 Introduction
    6.2 Regulatory Approval Process
    6.3 Major Ongoing Clinical Trials in the Market
    6.4 Major Funding Activities in the Market

7 Liquid Biopsy Market, By Cancer Type (Page No. - 54)
    7.1 Introduction
           7.1.1 Lung Cancer
    7.2 Breast Cancer
           7.2.1 Colorectal Cancer
           7.2.2 Prostate Cancer
           7.2.3 Liver Cancer
           7.2.4 Other Cancers

8 Liquid Biopsy Market, By Circulating Biomarker (Page No. - 69)
    8.1 Introduction
    8.2 Circulating Tumor Cells
    8.3 Extracellular Vesicles
    8.4 Circulating Tumor DNA (CTDNA)
    8.5 Other Biomarkers

9 Liquid Biopsy Market, By Products and Services (Page No. - 79)
    9.1 Introduction
           9.1.1 Reagents
    9.2 Instruments
           9.2.1 Services & Software

10 Liquid Biopsy Market, By End User (Page No. - 87)
     10.1 Introduction
     10.2 Reference Laboratories
             10.2.1 Hospitals and Physician Laboratories
             10.2.2 Academic and Research Centers
             10.2.3 Other End Users

11 Liquid Biopsy Market, By Region (Page No. - 95)
     11.1 Introduction
     11.2 North America
             11.2.1 U.S.
             11.2.2 Canada
     11.3 Europe
     11.4 Asia-Pacific
     11.5 Rest of the World (RoW)

12 Competitive Landscape (Page No. - 121)
     12.1 Overview
     12.2 Competitive Situation and Trends
             12.2.1 Agreements, Partnerships, and Collaborations
             12.2.2 New Product Launches
             12.2.3 Acquisitions
             12.2.4 Other Developments

13 Company Profiles (Page No. - 128)
(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*
     13.1 Introduction
     13.2 Biocept, Inc.
     13.3 Qiagen
     13.4 F. Hoffmann-La Roche AG
     13.5 Bio-Rad Laboratories Inc.
     13.6 Myriad Genetics
     13.7 Janssen Diagnostics, LLC.
     13.8 Tr0vagene Inc.
     13.9 Guardant Health Inc.
     13.10 Fraunhofer-Gesellschaft
     13.11 MDX Health SA

*Details on Marketsandmarkets View, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments Might Not Be Captured in Case of Unlisted Companies.

14 Appendix (Page No. - 150)
     14.1 Insights of Industry Experts
     14.2 Discussion Guide
     14.3 Other Developments
     14.4 Knowledge Store: Marketsandmarkets’ Subscription Portal
     14.5 Introducing RT: Real-Time Market Intelligence
     14.6 Available Customizations
     14.7 Related Reports


List of Tables (75 Tables)

Table 1 Liquid Biopsy Products Launched in Recent Years
Table 2 Funds Provided for Liquid Biopsy, 2013-2016
Table 3 Conferences and Awareness Programs on Liquid Biopsy
Table 4 Market: Inorganic Strategies (2015-16)
Table 5 Liquid Biopsy Clinical Trials
Table 6 Funding in Market
Table 7 Market Size, By Cancer Type, 2014–2021 (USD Million)
Table 8 Global Market Size for Lung Cancer, By Region, 2014–2021 (USD Million)
Table 9 North America: Market Size for Lung Cancer, By Country, 2014–2021 (USD Million)
Table 10 Impact of Aging on Breast Cancer Development
Table 11 Global Market Size for Breast Cancer, By Region, 2014–2021 (USD Million)
Table 12 North America: Market Size for Breast Cancer, By Country, 2014–2021 (USD Million)
Table 13 Global Market Size for Colorectal Cancer, By Region, 2014–2021 (USD Million)
Table 14 North America: Market Size for Colorectal Cancer, By Country, 2014–2021 (USD Million)
Table 15 Global Market Size for Prostate Cancer, By Region, 2014–2021 (USD Million)
Table 16 North America: Market Size for Prostate Cancer, By Country, 2014–2021 (USD Million)
Table 17 Global Market Size for Liver Cancer, By Region, 2014–2021 (USD Million)
Table 18 North America: Market Size for Liver Cancer, By Country, 2014–2021 (USD Million)
Table 19 Global Market Size for Other Cancers, By Region, 2014–2021 (USD Million)
Table 20 North America: Market Size for Other Cancers, By Country, 2014–2021 (USD Million)
Table 21 Market Size, By Circulating Biomarker, 2014–2021 (USD Million)
Table 22 Market Size for Circulating Tumor Cells, By Region, 2014–2021 (USD Million)
Table 23 North America: Market Size for Circulating Tumor Cells, By Country, 2014–2021 (USD Million)
Table 24 Market Size for Extracellular Vesicles, By Region, 2014–2021 (USD Million)
Table 25 North America: Market Size for Extracellular Vesicles, By Country, 2014–2021 (USD Million)
Table 26 Market Size for Circulating Tumor DNA, By Region, 2014–2021 (USD Million)
Table 27 North America: Market Size for Circulating Tumor DNA, By Country, 2014–2021 (USD Million)
Table 28 Market Size for Other Biomarkers, By Region, 2014–2021 (USD Million)
Table 29 North America: Market Size for Other Biomarkers, By Country, 2014–2021 (USD Million)
Table 30 Global Market Size, By Products & Services, 2014–2021 (USD Million)
Table 31 Global Liquid Biopsy Reagents Market Size, By Region, 2014–2021 (USD Million)
Table 32 North America: Liquid Biopsy Reagents Market Size, By Country, 2014–2021 (USD Million)
Table 33 Global Liquid Biopsy Instruments Market Size, By Region, 2014–2021 (USD Million)
Table 34 North America: Liquid Biopsy Instruments Market Size, By Country, 2014–2021 (USD Million)
Table 35 Global Liquid Biopsy Services & Software Market Size, By Region, 2014–2021 (USD Million)
Table 36 North America: Liquid Biopsy Services & Software Market Size, By Country, 2014–2021 (USD Million)
Table 37 Liquid Biopsy Market Size, By End User, 2014–2021 (USD Million)
Table 38 Liquid Biopsy Market Size for Reference Laboratories, By Region, 2014–2021 (USD Million)
Table 39 North America: Market Size for Reference Laboratories, By Country, 2014–2021 (USD Million)
Table 40 Market Size for Hospitals and Physician Laboratories, By Region, 2014–2021 (USD Million)
Table 41 North America: Market Size for Hospitals and Physician Laboratories, By Country, 2014–2021 (USD Million)
Table 42 Market Size for Academic and Research Centers, By Region, 2014–2021 (USD Million)
Table 43 North America: Market Size for Academic and Research Centers, By Country, 2014–2021 (USD Million)
Table 44 Market Size for Other End Users, By Region, 2014–2021 (USD Million)
Table 45 North America: Market Size for Other End Users, By Country, 2014–2021 (USD Million)
Table 46 Market Size, By Region, 2014–2021 (USD Million)
Table 47 North America: Market Size, By Country, 2014–2021 (USD Million)
Table 48 North America: Market Size, By Type of Cancer, 2014–2021 (USD Million)
Table 49 North America: Market Size, By Product, 2014–2021 (USD Million)
Table 50 North America: Market Size, By Circulating Biomarker, 2014–2021 (USD Million)
Table 51 North America: Market Size, By End User, 2014–2021 (USD Million)
Table 52 U.S.: Market Size, By Type of Cancer, 2014–2021 (USD Million)
Table 53 U.S.: Market Size, By Product, 2014–2021 (USD Million)
Table 54 U.S.: Market Size, By Circulating Biomarker, 2014–2021 (USD Million)
Table 55 U.S.: Market Size, By End User, 2014–2021 (USD Million)
Table 56 Canada: Market Size, By Type of Cancer, 2014–2021 (USD Million)
Table 57 Canada: Market Size, By Product, 2014–2021 (USD Million)
Table 58 Canada: Market Size, By Circulating Biomarker, 2014–2021 (USD Million)
Table 59 Canada: Market Size, By End User, 2014–2021 (USD Million)
Table 60 Europe: Market Size, By Type of Cancer, 2014–2021 (USD Million)
Table 61 Europe: Market Size, By Product, 2014–2021 (USD Million)
Table 62 Europe: Market Size, By Circulating Biomarker, 2014–2021 (USD Million)
Table 63 Europe: Market Size, By End User, 2014–2021 (USD Million)
Table 64 Asia-Pacific: Market Size, By Type of Cancer, 2014–2021 (USD Million)
Table 65 Asia-Pacific: Market Size, By Product, 2014–2021 (USD Million)
Table 66 Asia-Pacific: Market Size, By Circulating Biomarker, 2014–2021 (USD Million)
Table 67 Asia-Pacific: Market Size, By End User, 2014–2021 (USD Million)
Table 68 RoW: Market Size, By Type of Cancer, 2014–2021 (USD Million)
Table 69 RoW: Market Size, By Product, 2014–2021 (USD Million)
Table 70 RoW: Market Size, By Circulating Biomarker, 2014–2021 (USD Million)
Table 71 RoW: Market Size, By End User, 2014–2021 (USD Million)
Table 72 Agreements, Partnerships, and Collaborations, 2013–2016
Table 73 New Product Launches, 2013–2016
Table 74 Acquisitions, 2013-2016
Table 75 Other Developments, 2013–2016


List of Figures (74 Figures)

Figure 1 Research Design
Figure 2 Epidemiology Model
Figure 3 Market Size Estimation and Data Triangulation
Figure 4 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 5 Market Data Triangulation Methodology
Figure 6 Liquid Biopsy Market Size, By Product, 2016 vs 2021 (USD Million)
Figure 7 Market Size, By Cancer Type, 2016 vs 2021 (USD Million)
Figure 8 Market Size, By Circulating Biomarker, 2016 vs 2021 (USD Million)
Figure 9 Market Size, By End User, 2016 vs 2021 (USD Million)
Figure 10 Geographical Snapshot of the Market, 2016
Figure 11 Increasing Number of New Cancer Cases—Primary Growth Driver for the Market
Figure 12 Circulating Tumor Cells Segment to Account for the Largest Market Share in 2016
Figure 13 Reference Laboratories Segment Will Continue to Dominate the Market in 2021
Figure 14 Reagents Segment Dominates the Market in 2016
Figure 15 Circulating Tumor Cells Segment Accounts for the Largest Market Share in 2016
Figure 16 Asia-Pacific to Register the Highest Growth Rate in the Forecast Period
Figure 17 Market: Drivers, Restraints, Opportunities, Challenges
Figure 18 Increasing Number of New Cancer Cases Worldwide (2012-2020)
Figure 19 Cost Comparison Between Liquid and Incisional Biopsy
Figure 20 Relationship Between Liquid Biopsy Sensitivity and Number of Metastatic Sites
Figure 21 Discovery and Development of Medical Devices
Figure 22 New Cancer Cases, By Country (2012)
Figure 23 New Cancer Cases, By Country (2020)
Figure 24 New Cancer Cases Worldwide (2012 vs 2015 vs 2020)
Figure 25 Lung Cancer Will Continue to Account for the Largest Share in 2021
Figure 26 North America Will Continue to Dominate the Market for Lung Cancer By 2021
Figure 27 Asia-Pacific Offers Lucrative Opportunities in the Market for Breast Cancer
Figure 28 North America Will Continue to Lead the Liquid Biopsy Market for Colorectal Cancer in 2021
Figure 29 North America Will Continue to Lead the Liquid Biopsy Market for Prostate Cancer in 2021
Figure 30 North America Will Continue to Lead the Liquid Biopsy Market for Liver Cancer in 2021
Figure 31 New Cases of Other Cancer Types Worldwide (2012—2020)
Figure 32 North America Will Continue to Lead the Other Cancers Market in 2021
Figure 33 Circulating Tumor Cells to Account for the Largest Share of the Liquid Biopsy Market
Figure 34 North America Will Continue to Account for Largest Market Share in 2021
Figure 35 North America to Account for the Largest Market Share in 2021
Figure 36 North America Will Continue to Account for Largest Market Share in 2021
Figure 37 North America to Dominate the Market for Other Biomarkers
Figure 38 The Reagents Product Segment Will Continue to Account for the Largest Share of the Market in the Forecast Period
Figure 39 North America Will Continue to Dominate the Market for Liquid Biopsy Reagents During the Forecast Period
Figure 40 Asia-Pacific to Witness Highest Growth in the Liquid Biopsy Instruments Market By 2021
Figure 41 North America Will Continue to Dominate the Market for Liquid Biopsy Services & Software in 2021
Figure 42 Reference Laboratories Segment Will Continue to Dominate the Market
Figure 43 Asia-Pacific Reference Laboratories End-User Segment to Show Highest Growth
Figure 44 North America, the Largest Segment in the Hospital / Physician Laboratories Market
Figure 45 North America Will Continue to Dominate the Liquid Biopsy Market for Academic and Research Centers
Figure 46 Asia-Pacific to Grow at the Highest Rate in the Liquid Biopsy Market for Other End Users
Figure 47 North America to Account for the Largest Share of the Liquid Biopsy Market in 2016
Figure 48 North America Liquid Biopsy Market Snapshot
Figure 49 North American Lung Cancer Segment to Account for the Largest Share of the Liquid Biopsy Market in 2016
Figure 50 Circulating Tumor Cells Segment Expected to Account for the Largest Share of the North American Liquid Biopsy Market in 2016
Figure 51 Lung Cancer to Dominate U.S. Liquid Biopsy Market, By Cancer Type, Till 2021
Figure 52 Reference Laboratories End-User Segment to Account for the Largest Share of the U.S. Liquid Biopsy Market in 2016
Figure 53 Lung Cancer Will Continue to Dominate the Canadian Liquid Biopsy Market Till 2021
Figure 54 Reagents Account for the Largest Share of the Canadian Liquid Biopsy Market in 2016
Figure 55 Europe: Cancer Frequency, By Country, 2012 (Per 100,000 Population)
Figure 56 Medical Insurance Coverage of Major European Countries, 2013
Figure 57 Lung Cancer Segment to Account for the Largest Share of the Liquid Biopsy Market in 2016
Figure 58 Reference Laboratories, the Largest End-User Segment in the European Market
Figure 59 Asia-Pacific Liquid Biopsy Market Snapshot
Figure 60 Lung Cancer is Expected to Account for the Largest Share of the Asia-Pacific Liquid Biopsy Market in 2016
Figure 61 Circulating Tumor Cells Segment to Dominate Asia-Pacific Liquid Biopsy Market in 2016
Figure 62 Lung Cancer Will Dominate the RoW Liquid Biopsy Market Till 2021
Figure 63 Reagents Product Segment to Command Largest Share of the RoW Liquid Biopsy Market
Figure 64 Companies Adopted Agreements, Collaborations, and Partnerships as Their Key Growth Strategy Over the Last Four Years (2013-2016)
Figure 65 Agreements, Collaborations, and Partnerships - Key Growth Strategies Adopted By Players in the Liquid Biopsy Market
Figure 66 Geographic Revenue Mix of Top Four Market Players
Figure 67 Biocept, Inc.: Company Snapshot
Figure 68 Qiagen: Company Snapshot
Figure 69 Company Snapshot: F. Hoffmann-La Roche AG
Figure 70 Company Snapshot: Bio-Rad Laboratories Inc.
Figure 71 Myriad Genetics: Company Snapshot
Figure 72 Johnson & Johnson: Company Snapshot
Figure 73 Travogene Inc.: Company Snapshot
Figure 74 MDX Health: Company Snapshot

The liquid biopsy market is expected to reach USD 1.66 Billion by 2021 from USD 0.58 Billion in 2016, growing at a CAGR of 23.4% during the forecast period of 2016 to 2021. Technological advancements, increasing number of new cancer cases, availability of funding, growing awareness about liquid biopsy through conferences and government initiatives, and benefits of liquid biopsy over solid tumor biopsy are some of the major factors driving the growth of the market. However, the unclear reimbursement and regulatory scenario is a major area of concern in this market.

The liquid biopsy market is segmented based on cancer type, circulating biomarkers, products & services, end users, and regions. Based on cancer type, the market is segmented into lung cancer, breast cancer, colorectal cancer, prostate cancer, liver cancer, and other cancers (melanoma, bladder cancer, and ovarian cancer). In 2016, the lung cancer segment is expected to account for the largest share of the market primarily due to technological advancements and the growing demand for advanced diagnostic technologies among the large base of lung cancer patients.

Based on circulating biomarkers, the market is segmented into circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), Extracellular Vesicles (EVs), and other biomarkers (circulating RNA and proteins). In 2016, the circulating tumor cells segment is expected to account for the largest share of the global liquid biopsy market, followed by the circulating tumor DNA segment. Based on products & services, the market is segmented into instruments, reagents, and services and software.

Based on end user, the liquid biopsy market is segmented into reference laboratories, hospital/physician laboratories, academic and research centers, and other end users (public health laboratories, pathology laboratories, and small molecular laboratories).

Liquid Biopsy Market

In 2016, North America is expected to account for the largest share of the global liquid biopsy market. The large share of this regional segment can be attributed to factors such as increasing prevalence of cancer in the U.S. and Canada; easy accessibility and high adoption of advanced diagnostic technologies, such as PCR and NGS, among healthcare professionals; and continuous technological advancements in liquid biopsy. However, the Asia-Pacific market is estimated to witness the highest growth during the forecast period due to the increasing focus of global liquid biopsy players on this region.

Some of the key players operating in liquid biopsy market are Biocept Inc. (U.S.), Myriad Genetics (U.S.), QIAGEN (Netherlands), Roche (Switzerland), Bio-Rad Laboratories Inc. (U.S.), Trovagene Inc. (U.S.), Guardant Health, Inc. (U.S.), Janssen Diagnostics, LLC (U.S.), Fraunhofer-Gesellschaft (Germany), and MDxHealth SA (U.S.).

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Please visit http://www.marketsandmarkets.com/knowledge-process-outsourcing-services.asp to specify your custom Research Requirement

Connect With Us

Follow us on LinkedIn  Follow us on Facebook   Follow us on Twitter 
Live Chat Support


US : 1-888-600-6441
UK : 44-800-368-9399

Search reports



Access reports on all high
growth Medical Devices Markets on KnowledgeStore
Request Demo